



May 8, 2024

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc.

AnGes Inc. announced on April 12, 2024 that Eiger BioPharmaceuticals, Inc. (“Eiger”), the manufacturer and distributor of Zokinvy (lonafarnib), a drug for the treatment of Hutchinson-Gilford progeria syndrome and dysprocessing progeroid laminopathies, which is a premature aging syndrome in infants that is planned for marketing in Japan, has filed for protection under Chapter 11 of the U.S. Bankruptcy Code . We are pleased to announce that the sale of Eiger's “Zokinvy” business has been finalized.

Eiger filed for Chapter 11 of the U.S. Bankruptcy Code and has been in the process of selecting a transferee for the Zokinvi business, and has now selected Sentynl Therapeutics, Inc. (“Sentynl”), a U.S. biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd. With the U.S. Bankruptcy Court's approval of the assignment to Sentynl, Sentynl has acquired worldwide rights to “Zokinvy” and will be responsible for its manufacture and commercialization.

We plan to start selling “Zokinvy” in May 2024, having obtained manufacturing and marketing approval in Japan on January 18 of this year. Based on the number of patients expected to use the product, the number of this product expected to be needed in the immediate future has already been received in Japan. In accordance with this decision, MEDINET will take necessary actions including negotiations with Sentynl regarding “Zokinvy” and will make further announcements as details are finalized.

At this time, we do not expect this event to have any impact on our consolidated earnings forecast for the current fiscal year, as the products expected to be sold during the current fiscal year have already been received. However, we will promptly make an announcement if we expect a significant impact on our earnings in the future.

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.